Thank you. Operator, welcome to the presentation of Bactiguard's report for the third quarter of 2025.
Our CFO, Patrick Bach, and I will go through the presentation together, and we will have a Q&A session towards the end. Let's start with some high-level comments on the quarter, and Patrick will go into more financial details later in the presentation.
We have had another profitable quarter with EBITDA totaling 5.3 million SEK, and the investments we have made over the last two years in strengthening the organization and capabilities to support licensing have not jeopardized our margins or impacted profitability. Even though we do not yet demonstrate significant top-line growth, we deliver a strong EBITDA, and I am confident that we are equipped to execute on the opportunities for our infection prevention technology across our strategic therapeutic areas. Total revenues were just over 48 million, with licensing revenues of almost 30 million. Given our substantial US dollar exposure in the license business, the weaker US dollar continues to impact these revenues negatively. We also had an exceptionally strong third quarter in 2024, which set a high base for comparison.
Notably, this quarter is the third strongest of the last ten quarters from the partnership, with only Q3 and Q4 of 2024 being stronger. We remain positive about the trajectory of in-market sales.
Revenues from the Zimmer Biomet partnership were limited this quarter, as no milestone or minimum royalties were recognized during the quarter, as was expected.
However, the partnership with Zimmer Biomet is progressing, including in the expansion of the clinical evidence supporting the advantages of the Bactiguard-coated trauma implants. Newly published clinical study data benefits not just the ZNN Bactiguard, but adds a robust body of clinical evidence for our coating technology that also supports our business development activities. Wound Management had a slower quarter compared to Q3 2024, with revenues of 15.6 million, but it is still expected to deliver double-digit growth. I will come back to more detail on each of these highlights later in the presentation.
Before digging deeper into the third quarter, I would like to summarize why Bactiguard is a compelling investment opportunity beyond the fact that we are now a profitable business geared for growth.
Firstly, there is a clear need for solutions to reduce the burden on patients, on healthcare practitioners, and in costs to the healthcare system from infections. Secondly, the Bactiguard coating technology and Hydrocyn aqua line of products are differentiated from other solutions, and the coating technology has multiple levels of validation from robust clinical studies, demonstrated manufacturing scalability, successful commercialization, and continued validation in real-world use over the last 30 years. Thirdly, our coating platform is highly scalable with proven compatibility on multiple types of materials and applicability to multiple therapeutic areas, including those that are as different from each other as urology, catheters, and orthopedic implants. Our licensing business model also means high leverage in Bactiguard's scale as our partners reach commercialization stages, and once our technology is embedded, it is integral to the device, making the revenue stream sticky and long-lasting. Fourthly, we build from a positive EBITDA base with new growth verticals and development, putting us at an inflection point for value creation on both sides of our business.
I would also like to take a moment to reiterate our core value proposition.
We provide global medtech companies with advanced technology that helps prevent medical device-related infections. Bactiguard technology is an ultra-thin coating of the noble metals gold, silver, and palladium that has been demonstrated to work on multiple types of materials and devices and in different clinical settings.
We have, over time, coated more than 20 different materials with good outcomes, and more than 250 million devices have been coated for patient use.
Our technology has amassed a wealth of evidence of its safety and efficacy in reducing medical device-related infections. Some 100,000 people have been part of clinical trials, demonstrating up to 70% infection rate reductions.
And last, but certainly not least, in 30 years of real-world use, we have had zero adverse events related to the coating.
In short, it's a track record that gives confidence to our licensed partners.
For our licensing business, Bactiguard is focused on therapeutic areas where infection rates are relatively high and there is an urgent unmet medical need for effective infection prevention. Solution. Infection in these settings is linked to poor patient outcomes and, in severe cases, death, contributing to high healthcare costs and underscoring both the medical need and the market opportunity. Across these areas, there are clear applications suitable for our infection prevention technology and great potential to reduce medical device-related infections.
These areas also represent the strongest potential for both enhanced and future licensing partnerships, combining high clinical evidence with tangible commercial potential for Bactiguard.
Across the top of the partnership snapshot chart, our partnership stages outline the progress in our business development activities, matched against the relevant therapeutic area on the left.
Starting from the top, we have our partnership in orthopedics within the trauma area with Zimmer Biomet at commercial stages in selected markets, and we have full rights available for licensing to all orthopedic applications.
Outside of that, orthopedics represents a significant opportunity with an addressable market of nearly $40 billion.
This area involves a high volume of procedures and consequently, a high incidence of device-related infections. We see significant opportunities moving forward in this segment. Cardiology is one of our newer strategic therapeutic areas and represents great potential for Bactiguard.
With an addressable market of around $10 billion, cardiology includes a variety of implantable devices that are susceptible to infections, with reported infection rates of up to 7% for implantable electronic devices and up to 39% for ventricular assist devices. Despite a well-appreciated respect for infection prevention within the cardiology field, these infections pose major challenges, often leading to device failure that necessitates surgical intervention and places considerable strain on both patient recovery and healthcare resources. Last quarter, we initiated early feasibility work and are now progressing in non-clinical studies to demonstrate proof of concept in this area. In Urology, the Bactiguard-coated Foley catheter has already made a positive impact in preventing infections, especially in our long-standing partnership with Becton Dickinson.
Urology continues to present strong growth potential both for the already partnered Foley catheter application area and for other applications within the field, including vascular access. We already have an evidence base from the previously approved and marketed BIP central venous catheter, which we are building on with additional non-clinical studies. Even though we are very excited about the variety of early-stage testing that is ongoing, bringing medtech innovations to market is a long-term process that can take several years from initial testing to commercialization.
As mentioned in my CEO statement, the efforts we are making today and will continue to make in the coming quarters are building the foundation for future growth.
We are steadfast in our strategic direction, targeting therapeutic areas with significant unmet medical needs, and forming partnerships where Bactiguard infection prevention technology delivers clear and lasting value.
Now to give a bit more color on our commercial stage partnerships.
As I noted earlier in Q3, the revenues from this partnership bounced back compared to the second quarter, and the momentum in our collaboration with global medtech company Becton Dickinson continues to be strong. Looking at the 2025 progress so far, the partnership has advanced steadily for their core US market. BD has introduced a dedicated product website with a comprehensive section offering evidence-based insights into how Bactiguard-coated catheters help reduce infections, improve outcomes, and strengthen prevention protocols. The Bactiguard-coated catheters were also launched in India, where healthcare-associated infections and antimicrobial resistance remain major challenges.
The team has been actively working on transitioning this market, where we previously sold the Foley from Bactiguard to BD. Preparations for launch readiness in Europe are also ongoing, and we expect more market launches in the coming quarters. BD and Bactiguard continue to work closely together, sharing insights and jointly driving growth, and we remain fully aligned on growing the Bactiguard-coated Foley catheters business. Zimmer Biomet carries the Infection Solutions banner as high as we do, with this category being an important strategic pillar for them. Company-wide, the ZNN Bactiguard Trauma Nail system is part of the prevention focus area and continues to be commercially supported across Europe, including through Zimmer's exhibitions and educational symposia. At the annual meeting held in Barcelona this past September, multiple key strategic initiatives were discussed. Even though Q3 revenues from the Zimmer partnership were limited, we see in-market growth in sales of the ZNN Bactiguard orthopedic implants, and the partnership continues to make progress. Zimmer continues to work on increasing evidence supporting the Bactiguard technology through clinical studies with the ZNN Bactiguard trauma nail system in Europe. These studies are also part of the work towards transitioning to the MDR regulatory requirements for the CE mark in Europe, which continues according to plan. As a highlight for us this quarter through the Zimmer Biomet partnership, the publication of two independent studies in medical journals has further expanded the clinical evidence supporting the Bactiguard coated trauma.
Now, the study conducted at the Leeds Major Trauma Centre in the UK is the first clinical comparative evaluation of noble metal alloy coated nails in a high-risk orthopedic trauma population. The aim. The aim of this pilot study was to assess the clinical effectiveness of two commercially available coated tibia nails compared with non-coated implants. The single-center cohort study included 234 patients over a ten-year period.
All patients had tibial fractures considered at high risk of infection, and were treated with one of three types of implants. The coated trauma nail, ZNN Bactiguard, and antibiotic-releasing nail, or a standard uncoated tibial nail. The results showed that the Bactiguard coated nails had the lowest infection rate at 4.9%, compared to 7.8% for gentamicin coated nails and 13.2% for uncoated nails. Patients treated with Bactiguard coated implants also experienced fewer unplanned interventions due to complications, a lower nonunion rate, and no cases of anaerobic infections, which was a better outcome compared to both of the other treatment groups. While the study was not statistically powered for all outcomes, the data consistently confirm improved clinical results with Bactiguard coated nails. Another independent study recently published in the medical journal Injury was conducted at the Vall D'Hebron University Hospital in Barcelona, Spain.
The objective of this study was to evaluate the clinical outcome of a novel hybrid bone transport technique, using a Bactiguard coated nail for the treatment of infected segmental tibial bone defects, and it showed good outcomes without increasing complications. These studies add to the growing body of evidence supporting Bactiguard's non-releasing biocompatible coating technology as a superior tool in the fight against implant-associated infections. I also just wanted to note that the Bactiguard technology was featured in a real emergency situation, captured in a Netflix documentary series covering the London trauma hospital system called Critical Between Life and Death, where a Bactiguard coated implant was used in a patient involved in a motorcycle and bus collision.
While we expect to continue to see real patient outcomes published in medical journals, this unexpected but more accessible context was a gratifying recognition of Bactiguard's role in advancing infection prevention. The wound management portfolio had revenues of 15.6 million SEK, a decrease of 13% compared to Q3 last year, which was primarily related to a decline in suture sales. Hydrocyn aqua sales continued to expand, with growth delivered across all regions, and we continue to expect to deliver double-digit growth in wound management in line with our strategic targets. Our focus in the near term is on onboarding new distributors in multiple markets to support the clinically differentiated marketing and sales of the Hydrocyn aqua line of products, and capture the demand we see in wound cleansing and healing, as well as the future potential in surgical settings and peritoneal lavage.
And now I will hand over to Patrick to review our Q3 financial outcomes in more detail.